Compare DSX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | TTRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Greece | United States |
| Employees | 939 | 2 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.1M | 281.2M |
| IPO Year | N/A | N/A |
| Metric | DSX | TTRX |
|---|---|---|
| Price | $2.22 | $10.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 616.8K | 100.3K |
| Earning Date | 05-28-2026 | 05-31-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.28 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $2.57 |
| 52 Week High | $2.92 | $11.69 |
| Indicator | DSX | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 70.79 |
| Support Level | $2.17 | $3.28 |
| Resistance Level | $2.24 | $11.69 |
| Average True Range (ATR) | 0.07 | 1.12 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 90.00 | 66.13 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.